Merus N.V.向美国商业化伙伴治疗机构颁发癌症药物Zenecutuzumab许可证。 Merus N.V. licenses cancer drug Zenocutuzumab to Partner Therapeutics for U.S. commercialization.

Merus N.V.向NRG1聚变阳性癌症伙伴治疗机构颁发了将美国癌症药物Zenecututuzumab商业化的专有权利许可证。 Merus N.V. has licensed exclusive rights to commercialize its cancer drug, Zenocutuzumab, in the U.S. to Partner Therapeutics for NRG1 fusion-positive cancers. Merus将根据销售情况获得预付付款、里程碑和特许使用费。 Merus will receive upfront payments, milestones, and royalties based on sales. 此外,Merus宣布了另一种药物(Phoosemtamab)的新临床数据,显示头部和颈部癌症患者的最新结果。 Additionally, Merus announced new clinical data for another drug, petosemtamab, showing updated results in head and neck cancer patients.